---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-033168"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:46:35.458697+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Phase 2a biomarker data for neflamapimod in DLB; RewinD-LB topline due Dec 2024

## Summary
- Plasma GFAP significantly reduced by neflamapimod (p=0.015 vs placebo); reductions linked to clinical improvement.
- RewinD-LB Phase 2b trial fully enrolled; topline data expected December 2024.
- Study has >95% statistical power for primary endpoint (CDR-SB) after excluding patients with tau pathology.
- DLB affects >1.4M patients in U.S. and EU with no approved treatment, per CervoMed.

## SEC filing metadata
- accession: 0001437749-24-033168
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924033168/0001437749-24-033168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924033168/crvo20241104_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-033168
- JSON: https://secwatch.observer/filing/0001437749-24-033168.json
- Plain text: https://secwatch.observer/filing/0001437749-24-033168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.